First Tracks Biotherapeutics Recognized in BioSpace 2027 Best Places to Work List
First Tracks Biotherapeutics was named as one of the top 30 small employers in the life sciences industry in BioSpace's 2027 Best Places to Work list.
Stocks · News reference
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated bullish coverage on TRAX, BGSI, NPCE, CUE and NGVC, assigning Outperform/Buy ratings with price targets from $18 to $120.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Natural Grocers Supports Regional American Red Cross Flood Relief Efforts
Natural Grocers is launching an in-store fundraising campaign across 71 locations to support American Red Cross flood relief efforts in the Four Corners region.
Natural Grocers by Vitamin Cottage, Inc. Announces Fourth Quarter and Fiscal Year 2026 Earnings Conference Call and Webcast
Natural Grocers by Vitamin Cottage, Inc. has scheduled its fourth quarter and fiscal year 2026 financial results release and investor conference call for November 19, 2026.
Guggenheim Maintains Buy Rating and Raises Price Target for First Tracks Biotherapeutics
Guggenheim analyst Yatin Suneja maintained a 'Buy' rating on First Tracks Biotherapeutics and increased the price target from $100 to $110.
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the Q3 earnings
Analyst Price Target for First Tracks Biotherapeutics Raised to $75
Analysts have raised the 12-month price target for First Tracks Biotherapeutics to $75, reflecting a potential 62% upside based on recent closing prices.